The NM_000152.5:c.853C>T variant in GAA is a missense variant predicted to cause substitution of proline by serine at amino acid 285 (p.Pro285Ser). The highest population minor allele frequency in gnomAD is 0.00009 (African) which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion. REVEL (in silico meta predictor for missense changes) score = 0.757 which is higher than the LSD VCEP threshold for PP3, and therefore meets this criterion. At least two patients had documented GAA deficiency with <30% of normal mean control level of GAA activity in cultured fibroblasts (PP4_Moderate). Two individuals with Pompe disease have been reported who are compound heterozygous for the variant and a pathogenic variant in GAA, phase unknown; either c.2237G>A (p.Trp746Ter)(PMID: 21484825)(0.5 points) or c.1354_1372del19 (PMID: 21550241)(0.5 points), Total 1 point (PM3). This variant results in <5% GAA activity when expressed in COS cells, and was classified as Class C ("less severe") by Kroos et al, 2012 (PMID:22644586), meeting the ClinGen LSD VCEP criteria for PS3_Supporting. There is a ClinVar entry for this variant (Variation ID: 281052, 1 star review status) with 5 submitters, two classifying the variant as pathogenic, one as likely pathogenic, and one as a variant of uncertain significance. In summary, this variant meets the criteria to be classified as Likely Pathogenic for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Storage Disorders Variant Curation Expert panel (specifications Version 2.0): PP4_moderate, PP3, PM2_supporting, PM3, PS3_supporting.